Search

Search Constraints

You searched for: Author/Creator Nomdedeu, M.

Search Results

1. What is the Outcome of Patients in the Intermediate IPSS-R Score Group? Spanish Approach for Better Stratification with Classical Tools. (April 2017)

2. Calculating IPSS-R by Enumerating Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Prediction in MDS with Erythroid Predominance. (April 2017)

3. The Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts can be Improved by Considering Bone Marrow Blasts from Nonerythroid Cells. (April 2017)

4. Clinical and Biological Significance of Y Chromosome Loss in a Series of 2, 423 Male Patients with MDS and CMML. (April 2017)

5. Chromosomal Aberrations in Therapy-Related Myelodysplastic Syndromes – Relations to Primary Disease, Therapy and Prognostic Significance. (April 2017)

6. Topic: AS02-Epidemiology: COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS). (September 2021)

7. 90 INTENSIVE CHEMOTHERAPY VERSUS NO INTENSIVE TREATMENT IN HIGH RISK MYELODYSPLASTYC SYNDROME (MDS) NO-HSCT CANDIDATES. (April 2015)

8. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. Issue 5 (September 2015)

9. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS). (May 2023)